These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26449765)

  • 1. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
    Valtorta E; Martino C; Sartore-Bianchi A; Penaullt-Llorca F; Viale G; Risio M; Rugge M; Grigioni W; Bencardino K; Lonardi S; Zagonel V; Leone F; Noe J; Ciardiello F; Pinto C; Labianca R; Mosconi S; Graiff C; Aprile G; Frau B; Garufi C; Loupakis F; Racca P; Tonini G; Lauricella C; Veronese S; Truini M; Siena S; Marsoni S; Gambacorta M
    Mod Pathol; 2015 Nov; 28(11):1481-91. PubMed ID: 26449765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.
    Tosi F; Sartore-Bianchi A; Lonardi S; Amatu A; Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Torri V; Marrapese G; Valtorta E; Cassingena A; Cappello G; Bonoldi E; Vanzulli A; Regge D; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Marsoni S; Siena S
    Clin Colorectal Cancer; 2020 Dec; 19(4):256-262.e2. PubMed ID: 32919890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
    Sartore-Bianchi A; Lonardi S; Martino C; Fenocchio E; Tosi F; Ghezzi S; Leone F; Bergamo F; Zagonel V; Ciardiello F; Ardizzoni A; Amatu A; Bencardino K; Valtorta E; Grassi E; Torri V; Bonoldi E; Sapino A; Vanzulli A; Regge D; Cappello G; Bardelli A; Trusolino L; Marsoni S; Siena S
    ESMO Open; 2020 Sep; 5(5):e000911. PubMed ID: 32988996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of
    Owen DR; Wong HL; Bonakdar M; Jones M; Hughes CS; Morin GB; Jones SJM; Renouf DJ; Lim H; Laskin J; Marra M; Yip S; Schaeffer DF
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29438965
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
    JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
    Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
    Cenaj O; Ligon AH; Hornick JL; Sholl LM
    Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal Cancer Yields to Dual HER2 Blockade.
    Cancer Discov; 2016 Jul; 6(7):OF5. PubMed ID: 27165728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.
    Sun Q; Li Q; Gao F; Wu H; Fu Y; Yang J; Fan X; Cui X; Pu X
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):579-592. PubMed ID: 36018511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
    J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review.
    Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
    JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma HER2 (
    Siravegna G; Sartore-Bianchi A; Nagy RJ; Raghav K; Odegaard JI; Lanman RB; Trusolino L; Marsoni S; Siena S; Bardelli A
    Clin Cancer Res; 2019 May; 25(10):3046-3053. PubMed ID: 30808777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
    Satoh T; Xu RH; Chung HC; Sun GP; Doi T; Xu JM; Tsuji A; Omuro Y; Li J; Wang JW; Miwa H; Qin SK; Chung IJ; Yeh KH; Feng JF; Mukaiyama A; Kobayashi M; Ohtsu A; Bang YJ
    J Clin Oncol; 2014 Jul; 32(19):2039-49. PubMed ID: 24868024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
    Press MF; Ellis CE; Gagnon RC; Grob TJ; Buyse M; Villalobos I; Liang Z; Wu S; Bang YJ; Qin SK; Chung HC; Xu J; Park JO; Jeziorski K; Afenjar K; Ma Y; Estrada MC; Robinson DM; Scherer SJ; Sauter G; Hecht JR; Slamon DJ
    Mol Cancer Ther; 2017 Jan; 16(1):228-238. PubMed ID: 27811012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer.
    Liu F; Ren C; Jin Y; Xi S; He C; Wang F; Wang Z; Xu RH; Wang F
    Virchows Arch; 2020 Mar; 476(3):391-398. PubMed ID: 31720832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.